Abstract
The objective of this study was to evaluate the Canadian Rheumatology Association Choosing Wisely recommendation concerning anti-nuclear antibody (ANA) testing. Patients with joint pain/stiffness/swelling were assessed to determine if ANA testing was indicated. An a priori threshold was set before ANA testing would be considered. Those who did not have ANA testing ordered were followed for 1 year to determine if any of them went on to have a diagnosis of systemic lupus erythematosus (SLE) or other connective tissue disease. A parallel study was conducted with a similar a priori threshold for the use of rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) antibody testing in the diagnosis of rheumatoid arthritis (RA), and again, patients were followed for 1 year. A total of 866 subjects were examined, 509 females (58.8 %) and 357 males (41.2 %). The mean age of the group was 47.5 ± 16.8 years. The mean duration of symptoms was 12.0 ± 5.6 weeks. Of the 866 subjects, 68 met an a priori threshold for ordering ANA, RF, and anti-CCP testing. Of these 68, there was a newly diagnosed case of SLE, 4 newly diagnosed cases of RA, and 3 cases of polymyalgia rheumatica. The remaining 798 subjects were followed for approximately 1 year and none developed evidence of SLE, RA, or other connective tissue disease. In the evaluation of non-specific musculoskeletal symptoms, setting an a priori threshold for ordering serology in keeping with the spirit of the Canadian Rheumatology Association Choosing Wisely recommendation for antibody testing results in a very low risk of missing a case of systemic lupus erythematosus or rheumatoid arthritis.
Similar content being viewed by others
References
Canadian Institute for Health Information. Health spending in Canada in 2013. [Internet. Accessed December 22, 2014.] Available from: www.cihi.ca/CIHI-ext-portal/internet/en/document/spending+and+health+workforce/spending/release_29oct13_infogra1pg
Dartmouth Medical School Center for the Evaluative Clinical Sciences. The care of patients with severe chronic illness: an online report on the Medicare Program by the Dartmouth Atlas Project. [Internet. Accessed December 22, 2014.] Available from: www.dartmouthatlas.org/downloads/atlases/2006_Chronic_ Care_Atlas.pdf
Kale MS, Bishop TF, Federman AD, Keyhani S (2011) “Top 5” lists top $5 billion. Arch Intern Med 171:1858–9
Welch HG, Schwartz L, Woloshin S (2011) Overdiagnosed: making people sick in the pursuit of health. Beacon, Boston
Chow SL, Thorne C, Bell MJ, Ferrari R, Bagheri Z, Boyd T et al (2015) Choosing wisely Canada. Canadian rheumatology association: five things physicians and patients should question. J Rheumatol. doi:10.3899/jrheum.141140, Published online January 27
Suarez-Almazor ME, Gonzalez-Lopez L, Gamez-Nava JI, Belseck E, Kendall CJ, Davis P (1998) Utilization and predictive value of laboratory tests in patients referred to rheumatologists by primary care physicians. J Rheumatol 25:1980–5
Kunihiro Nishimura K, Sugiyama D, Kogata Y, Tsuji G, Nakazawa T, Siago K et al (2007) Meta-analysis: diagnostic accuracy of anti–cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 146:797–808
Petri M, Obai AM, Alarcón GS, Gordon C, Merril JT, Fortin PR et al (2012) Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 64:2677–86
Daniel Aletaha D, Neogi T, Silman AJ, Funovits J, Fleson DT, Bingham CO et al (2010) Rheumatoid arthritis classification criteria. Arthritis Rheum 62:2569–81
Yazdany J, Schmajuk G, Robbins M, Daikh D, Beall A et al (2013) Choosing wisely: the american college of Rheumatology’s Top 5 list of things physicians and patients should question. Arthritis Care Res 65:329–39
Myckatyn SO, Russell AS (2003) Outcome of positive antinuclear antibodies in individuals without connective tissue disease. J Rheumatol 30:736–9
Humphreys JA, Verstappen SM, Hyrich KL, Chipping JR, Marshall T, Symmons D (2013) The incidence of rheumatoid arthritis in the UK: comparisons using the 2010 ACR/EULAR classification criteria and the 1987 ACR classification criteria. Results from the Norfolk arthritis register. Ann Rheum Dis 72:1315–20
Scolnik M, Marin J, Valeiras SM, Marchese MF, Talani AS et al (2014) Incidence and prevalence of lupus in Buenos Aires, Argentina: a 11-year health management organisation-based study. Lupus Sci Med 1(1):e000021. doi:10.1136/lupus-2014-000021
Funding
None
Disclosures
None
Author contributorship
RF is responsible for all aspects of the research and manuscript.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ferrari, R. Evaluation of the Canadian Rheumatology Association Choosing Wisely recommendation concerning anti-nuclear antibody (ANA) testing. Clin Rheumatol 34, 1551–1556 (2015). https://doi.org/10.1007/s10067-015-2985-z
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-015-2985-z